Effects of progesterone and R2323 on the development of dimethylbenzanthracene-induced mammary tumors.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000378:metabolism; D005260:Female; D005867:Gestrinone / Q000627:therapeutic use*; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism; D009651:Norpregnatrienes / Q000627:therapeutic use*; D011374:Progesterone / Q000633:toxicity*; D011388:Prolactin / Q000378:metabolism; D011397:Promegestone / Q000378:metabolism; D051381:Rats; D011956:Receptors, Cell Surface / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
D009651:Norpregnatrienes; D011956:Receptors, Cell Surface; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D005867:Gestrinone; D011374:Progesterone; D004958:Estradiol; D015127:9,10-Dimethyl-1,2-benzanthracene; D011388:Prolactin; D011397:Promegestone